Evidence map›Paper›PMID 38032322›Full record

ArticleTranslational vision science & technology2023

Development of LuxIA, a Cloud-Based AI Diabetic Retinopathy Screening Tool Using a Single Color Fundus Image.

Joseph P M Blair, Jose Natan Rodriguez, Romina M Lasagni Vitar, Marc A Stadelmann, Rodrigo Abreu-González, Juan Donate, Carlos Ciller, Stefanos Apostolopoulos, Carlos Bermudez, Sandro De Zanet

Open access · goldAbstract read
In one paragraph

Article in Translational vision science & technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Joseph P M BlairRetinAI Medical AG, Bern, Switzerland.
Jose Natan RodriguezDepartment of Information Technology, Nuestra Señora de la Candelaria University Hospital, Santa Cruz de Tenerife, Canarias, Spain.
Romina M Lasagni VitarRetinAI Medical AG, Bern, Switzerland.
Marc A StadelmannRetinAI Medical AG, Bern, Switzerland.
Rodrigo Abreu-GonzálezDepartment of Ophthalmology, Nuestra Señora de la Candelaria University Hospital, Santa Cruz de Tenerife, Canarias, Spain.
Juan DonateDepartment of Ophthalmology, Nuestra Señora de la Candelaria University Hospital, Santa Cruz de Tenerife, Canarias, Spain.
Carlos CillerRetinAI Medical AG, Bern, Switzerland.
Stefanos ApostolopoulosRetinAI Medical AG, Bern, Switzerland.
Carlos BermudezDepartment of Information Technology, Nuestra Señora de la Candelaria University Hospital, Santa Cruz de Tenerife, Canarias, Spain.
Sandro De ZanetRetinAI Medical AG, Bern, Switzerland.
Hospital Universitario Nuestra Señora de Candelaria · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Diabetic retinopathy (DR) is the leading cause of vision impairment in working-age adults. Automated screening can increase DR detection at early stages at relatively low costs. We developed and evaluated a cloud-based screening tool that uses artificial intelligence (AI), the LuxIA algorithm, to detect DR from a single fundus image. Methods: Color fundus images that were previously graded by expert readers were collected from the Canarian Health Service (Retisalud) and used to train LuxIA, a deep-learning-based algorithm for the detection of more than mild DR. The algorithm was deployed in the Discovery cloud platform to evaluate each test set. Sensitivity, specificity, accuracy, and area under the receiver operating characteristic curve were computed using a bootstrapping method to evaluate the algorithm performance and compared through different publicly available datasets. A usability test was performed to assess the integration into a clinical tool. Results: Three separate datasets, Messidor-2, APTOS, and a holdout set from Retisalud were evaluated. Mean sensitivity and specificity with 95% confidence intervals (CIs) reached for these three datasets were 0.901 (0.901-0.902) and 0.955 (0.955-0.956), 0.995 (0.995-0.995) and 0.821 (0.821-0.823), and 0.911 (0.907-0.912) and 0.880 (0.879-0.880), respectively. The usability test confirmed the successful integration of LuxIA into Discovery. Conclusions: Clinical data were used to train the deep-learning-based algorithm LuxIA to an expert-level performance. The whole process (image uploading and analysis) was integrated into the cloud-based platform Discovery, allowing more patients to have access to expert-level screening tools. Translational Relevance: Using the cloud-based LuxIA tool as part of a screening program may give diabetic patients greater access to specialist-level decisions, without the need for consultation.

Indexed as

Diabetes MellitusDiabetic RetinopathyTool Use BehaviorAdultAlgorithmsArtificial IntelligenceCloud ComputingHumans

Identifiers

PMID38032322
PMCPMC10691390
OpenAlexW4389180037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.